Off-Label Demand, On-Label Costs GLP-1s are clinically appropriate for some members, particularly those with type 2 diabetes or obesity-related health risks
Food and Drug Administration cleared Ascletis Pharma to start a Phase 1 clinical trial of ASC35 , a once-monthly subcutaneous peptide that activates both the GLP-1 and GIP receptors
Polekhina G, Board PG, Gali RR, Rossjohn J, Parker MW: Molecular basis of glutathione synthetase deficiency and a rare gene permutation event
Natural product andrographolide alleviated APAP-induced liver fibrosis by activating Nrf2 antioxidant pathway
The mechanism of anorexigenic action of OXM is not known but it may involve the suppression of plasma ghrelin levels (91)
In men with known infertility, a semen analysis provides objective data before and after metabolic intervention